Synergistic protective effect of astragaloside IV–tetramethylpyrazine against cerebral ischemic-reperfusion injury induced by transient focal ischemia  by Yang, Jiehong et al.
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Ethnopharmacological  relevance:  Astragaloside  IV  and  tetramethylpyrazine  have  been  extensively  used  in
the cardio-cerbrovascular  diseases  of  medicine  as  a  chief  ingredient  of  glycoside  or alkaloid  formulations
for  the  treatment  of  stroke  and  myocardial  ischemia  diseases.
Aim  of  the  study:  To  investigate  the  effects  of  astragaloside  IV  (ASG  IV) and  tetramethylpyrazine  (TMPZ)
on  cerebral  ischemia-reperfusion  (IR)  injury  model  in  rat  model.
Materials  and  methods:  Rats  were  randomly  divided  into  the  following  ﬁve  groups:  sham  group,  IR group
and  treatment  group  including  ASG  IV,  ASG  IV–TMPZ  and  nimodipine  treatment.  The  therapeutic  effect
was evaluated  by  micro-positron  emission  tomography  (Micro-PET)  using 18F-ﬂuoro-2-deoxy-d-glucose.
The neurological  examination,  infarct  volume  and  the  levels  of  oxidative  stress-  and  cell  apoptosis-related
molecules  were  assessed.
Results:  Micro-PET  imaging  showed  that  glucose  metabolism  in  the right  hippocampus  was  signiﬁcantly
decreased  in  the  IR  group  compared  to  the sham  group  (P <  0.01).  ASG  IV  and  ASG  IV–TMPZ  treatments
reversed  the  decreased  glucose  metabolism  in  the  model  group  (P < 0.05  and  P <  0.01,  respectively).  IR
induced  the  increase  of Caspase-3  mRNA  levels,  MDA  content  and  iNOS  activity,  but  it caused  the  decrease
of SOD  activity  and  Bcl-2  expression  compared  the  sham  group  (P <  0.01).  ASG  IV–TMPZ  and  ASG IV
reversed  the  IR-induced  changes  of  these  parameters,  i.e.  the  down  regulation  of  Caspase-3  mRNA,  MDA
content  and  iNOS activity,  and  the  up regulation  of  SOD  activity  and  Bcl-2  expression  (P  < 0.05).
Conclusion:  This  study  showed  that  ASG  IV–TMPZ  played  a  pivotal  synergistic  protective  role  against  focal
sion  cerebral  ischemic  reperfu
. Introduction
Cerebral ischemia-reperfusion (IR) injury often causes irre-
ersible brain damage, and the cascade of events leading to neu-
onal injury and death in brain ischemia includes interruption of the
erebral blood ﬂow, the depletion of energy stores excitotoxicity,
ree radical-induced neuronal damage, inﬂammation, apoptosis,
nd necrosis. We  have demonstrated that chuanxiongzine-
uerarin treatment exhibited signiﬁcant neuroprotective effect
Abbreviations: IR, ischemia-reperfusion; ASG IV, astragaloside IV; TMPZ,
etramethylpyrazine; SOD, superoxide dismutase; MDA, malondialdehyde; iNOS,
nduced nitric oxide synthase; 18F-FDG, 18F-ﬂuoro-2-deoxy-d-glucose; PET, positron
mission tomography; ELISA, enzyme-linked immunosorbent assay; TTC, triphenyl-
etrazolium chloride.
∗ Corresponding author at: Institute of Cardio-Cerbrovascular Diseases, Zhejiang
hinese Medical University, 548 Binwen Road, Hangzhou, Zhejiang 310053, China.
ax: +86 0571 86613712.
E-mail addresses: ajinistom@gmail.com (J. Li), wanhaitong@zjtcm.net (H. Wan).
1 These authors contributed equally to this work.
378-8741     © 2011 Elsevier Ireland Ltd.  
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Open access under CC BY-NC-ND license.damage  in  a  rat  experimental  model.
© 2011 Elsevier Ireland Ltd. 
compared with single puerarin use in IR model (Wan  et al.,
2008). This protective effect of chuanxiongzine-puerarin on cere-
bral ischemia was  assumed to be mediated by the inhibition of
free radicals formation, and other mechanisms. However, it has
found that glucose metabolism in the brain is closely related
to neuronal activity (Chugani et al., 1991), we used 18F labeled
2-deoxy-2-ﬂuoro-d-glucose (18F-FDG) that reﬂects the state of glu-
cose metabolism (Rohren et al., 2004) to evaluate the effects both
ASG IV and TMPZ on the cerebral ischemia-reperfusion injury.
As we  all know, B-cell lymphoma/leukemia-2 genes (Bcl-2), a
protooncogene, plays an important role in inhibiting apoptosis and
relieving cell death. Over-expression of Bcl-2 can enhance the cells
that observed by the majority of resistance to cytotoxic factors.
This discovery led to the recognition of apoptosis in a variety of
signal transduction pathways, and provided the access road or the
intersection point of regulation by Bcl-2. In addition, Bcl-2 over-
Open access under CC BY-NC-ND license.expression can reduce the oxygen free radicals and lipid peroxide
formation. It inhibits the trans-membrane calcium ﬂow. Further-
more, it has found that Bcl-2 has a neuroprotective roles against
ischemic brain injury through the reduction of neuronal apoptosis
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Han et al., 2002), and decrease free radical induced by neuronal
amage (Ginsberg, 2001).
ASG IV, a glycoside of cycloartane-type triterpene isolated from
he root of Astragalus membranaceus (Fisch). Bunge,  which used
xtensively in traditional Chinese medicine, it helps to speed heal-
ng and treat diabetes mellitus (Liu et al., 2004; Shao et al., 2004).
lso it helps to improve the functioning of the lungs, adrenal
lands and the gastrointestinal tract. Whats more, it could increase
etabolism, promote healing of wounds and injuries, and reduce
atigue (Balch, 2006). ASG IV has been reported to decrease the level
f malondialdehyde which is an indicator of lipid peroxidation, and
ncrease the levels of the antioxidant enzymes glutathione peroxi-
ase, superoxide dismutase; moreover, it decreased expression of
ccludin and zonae occludens-1, the tight junction proteins in brain
icro-vascular endothelial cells (Luo et al., 2004; Qu et al., 2009).
MPZ, a type of Chinese herb also used for the treatment of ischemic
erebral vascular disorders (Ho et al., 1989).
In this study, the neuronal activity, antioxidant, and anti-
poptosis potential effects of ASG IV–TMPZ were mainly inves-
igated in a rat model of transient cerebral ischemia-reperfusion
nduced by middle cerebral artery occlusion (MCAO).
. Materials and methods
.1. Animals
Male Sprague–Dawley rats weighing 280 ± 20 g, were individ-
ally maintained in an accredited animal husbandry facility that
as approved by the Animal Center of Zhejiang Chinese Medical
niversity (Laboratory animal certiﬁcate: scxk 2008-0115) with
 12-h light/dark environment. A total of 30 rats were randomly
ivided into ﬁve groups: sham operation group, cerebral IR group,
reatment groups including ASG IV, ASG IV–TMPZ and nimodipine
reatment). Animal care and surgical procedure were performed in
ccordance with the National Institute of Health Guide for the Care
nd Use of Laboratory Animals (NIH Publications No. 80-23) revised
n 1996. Formal approval to conduct the experiments was obtained
rom the University Animal Subjects Review Board. All efforts
ere made to minimize the number of animals used and their
uffering.
.2. Drugs and reagents
The SOD kit (Lot No. 20090928) and MDA  kit (Lot No. 20090928)
ere provided by Nanjing Jiancheng Biological Engineering Insti-
ute (Nanjing, China). Rat iNOS ELISA kit (Lot No. 501199) was
ought from Shanghai Ximei Biotechnology Ltd. (Shanghai, China).
igustrazine hydrochloride injection was purchased from Tri-
ion Pharmaceutical Co., Ltd., Harbin (Lot No. 090923A, Harbin,
eilongjiang, China), nimodipine injection was purchased from
ayer Healthcare AG (Leverkusen, Germany, Lot No. BXBSTX1
3), and ASG IV was prepared by semi-preparative HPLC agi-
ent 1200 (diameter of 30 mm,  length of 100 mm,  5 m particle
ize), Biological and Pharmaceutical Engineering Laboratory, Zhe-
iang Medical University, Zhejiang, China). 18F-FDG was produced
y the Department of Nuclear Medicine, Second Afﬁliated Hospi-
al, Zhejiang University College of Medicine, Hangzhou, Zhejiang,
hina.
.3. MCAO rat modeling and administration1% pentobarbital sodium solution (40 mg/kg) was used with
n intraperitoneal injection to the rats (Belayev et al., 1996). We
xposed the right common artery, external carotid artery and inter-
al carotid artery, respectively, under sterile conditions. A nylonmacology 140 (2012) 64– 72 65
ﬁlament thread (SP 184, 4-0) was  inserted into the right exter-
nal carotid artery and was carefully maneuvered into the internal
carotid artery. After 60 min  of MCAO, the nylon ﬁlament was  taken
out and the blood was reﬂowed. The rats in sham group were
prepared by the MCAO method except inserting the nylon ﬁla-
ment thread. The sham group and IR group rats were administered
the same dose of sterile saline. The dose of the drugs in treat-
ment groups were as follows: ASG IV was  20 mg/kg and TMPZ was
10 mg/kg in ASG IV–TMPZ group in order, ASG IV was 20 mg/kg in
single ASG IV group, and nimodipine was used by 10 mg/kg body
weight. All the drugs were intraperitoneally injected for each group
with the same volume (2 mL)  at 0, 12 h, 1 d, 2 d, 3 d, till to 7 d after
reperfusion.
2.4. Neurologic evaluation
A neurological examination was performed after 24-h of cere-
bral IR according to the method described by Longa et al. (1989).  The
neurological ﬁndings were scored on a 5-point scale: rats with no
neurologic deﬁcit scored 0, rats with (failure to extend left forepaw
fully) a mild focal neurologic deﬁcit scored 1, rats with (circling
to the left) a moderate focal neurologic deﬁcit scored 2, rats with
(falling to the left) a severe focal deﬁcit scored 3. Rats with a score
of 4 did not walk spontaneously and had a depressed level of con-
sciousness.
2.5. Micro-PET imaging
A total of 15 rats with cerebral IR injury were imaged by micro-
positive emission tomography (micro-PET) using 18F-FDG. Rats
were maintained on 2% isoﬂurane in oxygen, and then injected 18F-
FDG from tail vein. After an uptake period of 30 min, the rat was
placed in a spread prone position and scanned with the micro-PET
R4 (Concorde Microsystems, Knoxville, TN, USA), which consists
of a 15-cm diameter ring of 96 position-sensitive -ray scintilla-
tion detectors, providing a 10.8-cm trans axial, and a 7.8-cm axial
ﬁeld of view with image resolution at less than 1.8 mm.  Brieﬂy, we
injected 22.2–25.9 MBq  FDG into the tail vein of the rat and put
it back in a quiet room for 30 min  for glucose uptake. Ten-minute
static acquisition was performed in 3D mode. Corrections for dead
time, random scattering, and attenuation were performed. Micro-
PET image studies were reconstructed using a statistical maximum
a posteriori probability algorithm. The ratio of the regions of
interest (ROIs) in the temporal lobe, apical lobe, frontal lobe to
cerebellum was calculated for each scan using ASIPro 6.0.5.0 soft-
ware (CTI Concorde Microsystems, LLC proﬁle in Knoxville, TN,
USA) that is matched to 3D Micro-PET images at the Medical PET
Center of Zhejiang University. These ROIs were drawn and calcu-
lated by the author who  had extensive experience in manual ROIs
deﬁnition.
2.6. Triphenyltetrazolium chloride assessment
Rats were anesthetized, killed by rapid decapitation, and
the brain was  collected at 7 d after reperfusion. We  improved
the methods and refrigerated the brains at −20 ◦C, then sliced
into 2-mm thick coronal section and stained with 2% 2,3,5-
triphenyltetrazolium chloride solution for 10 min at 37 ◦C and ﬁxed
in 4% paraformaldehyde at 4 ◦C overnight (Bederson et al., 1986).
After ﬁxation these brain slices were scanned using a ﬂat-bed scan-
ner. Infarct volume was quantiﬁed with the professional image
analysis software. Infarct volumes were calculated by summation
of the infarct areas in six brain slices and integrated by thickness
(2 mm)  slightly.
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Table 1
Values of ﬁve groups of neurological deﬁcit after reperfusion.
Group n Neurologic score
Sham group 10 0.20 ± 0.42
Model group 10 3.40* ± 0.52
Astragaloside IV group 10 2.40** ± 0.51
Astragaloside IV–tetramethylpyrazine 10 1.80*** ± 0.42
Nimodipine group 10 1.60** ± 0.51
Values are mean ± SD.
* P < 0.01; signiﬁcantly higher compared with values of sham operation group.
** P < 0.01; signiﬁcantly lower compared with values of model group.6 J. Yang et al. / Journal of Ethn
.7. Determination of oxidative stress and iNOS
After MCAO under anesthesia, the rats were decapitated 7 d later
nd the brains were quickly taken out, and stored at −80 ◦C. The
rain tissue was homogenated and the supernatant was  collected
o assay SOD with xanthine oxidase method, MDA  with thiobarbi-
uric acid method, and iNOS with ELISA method according to the
anufacturers’ instruction.
.8. RNA isolation and real-time quantitative PCR
The rats were decapitated after 24 h of cerebral I/R injury, the
rains were taken out and the cortex was dissected from the
psilateral and contralateral hemispheres, separately. The samples
ere immediately stored at −80 ◦C for further use. Caspase-3
ene (forward, 5′-CTGGACTGCGGTATTGAGAC-3′, 20 bp; reverse,
′-CCGGGTGCGGTAGAGTAAGC-3′, 20 bp, GenBank Accession
o. NC005115.2) and -actin (forward, 5′-CCGTAAAGACCTC-
ATGCCAACA-3′, 23 bp; reverse 5′-TAGGAGCCAGGGCAGTAATC-3′,
0 bp, GenBank Accession No. EF156276.1). -Actin was  used as
n internal control for all experiments. Total RNA was  extracted
ith Trizol reagent according to the manufacturer’s recommended
rocedures. About 100 mg  of total RNA were segregated by Two
tep RT-PCR kit (Cat No. BSB05MI, Hangzhou Bayer Technology Co.,
td.) was reverse transcribed using an M-MLV  First Strand cDNA
ynthesis (Taq DNA Polymerase Kit, Lot 00043711, Fermentas
evert AidTM, Lithuania MBI). Quantitative PCR was performed
sing MJ  Mini personal Termal (BIO-RAID Ltd., American); Reac-
ion system: iQ SYBR Gene surpmix 12 L, upstream primer 1 L,
ownstream primer 1 L, cDNA template 1 L, starile water 10 L,
otal 25 L; reaction conditions: pre-incubation at 95 ◦C 3 min;
ncubation at 95 ◦C 10 s, incubate at 61 ◦C 50 s; plate read; go to
ine 2 for 40 cycles; melting curve from 65 ◦C to 95 ◦C, read every
.5 ◦C, hold 5 s. All experiments were performed three times, and
sed quantitative analysis software processed data. Through the
elative quantity (RQ = 2−Ct) calculate the target gene (calibra-
or) and compare the differences in gene expression by multiples
f the reference factor. The -actin gene as a restricted reference
aterials, each sample Ct = Ct (target gene) − Ct (-actin), and
he Ct = Ct (target gene) − Ct (calibrator).
.9. Immunohistochemistry
The sections were stained with ENVision (Dako-Cytomation,
lostrup, Denmark) two-step strategy and high-temperature anti-
en retrieval. Parafﬁn-embedded sections with 5-m thickness
ere deparafﬁnized twice, 10 min  each in 100% xylene, and then
ehydrated with 100% ethanol for 5 min, 95% for 3 min, and 80%
or 5 min. After 2–5 min  soaking in distilled water, the sections
ere put into the pressure cooker ﬁlled with 1000 mL  of boil-
ng sodium citrate buffer (pH 6.0) and heated under pressure for
 min  after steaming and then cooled. The sections were rinsed
or 2–3 min  with phosphate-buffered saline. Then the primary
abbit-anti-rat Bcl-2 monoclonal antibody, (Wuhan Boster Biolog-
cal Technology, Ltd., Hubei, China) was applied overnight at room
emperature. After 2–5 min  soaking in distilled water, and 2–3 min
insing in PBS for three times, the sections were incubated with
econdary antibody [goat-anti-rabbit polyclonal antibody (Wuhan
oster Biological Technology, Ltd., Hubei, China)] for 2 h at 37 ◦C
etween 2–3 min  rinsings in PBS for 3 times, with diaminoben-
idine chromagen added, soaking in distilled water, hematoxylin
tained 2–5 min  differentiated with 1% hydrochloric acid alco-
ol, and dehydrated, transparent, blue-based, coverslipped with
lycerin, the sections were observed and examined under a light
icroscope.*** P < 0.01; signiﬁcantly lower compared with values of model group and astraga-
loside IV group.
2.10. Statistical analysis
All data are showed as mean ± SEM and are accompanied
by the number of observations. Student’s unpaired t-test was
used to determine the differences between two groups. In more
than 2 groups, the data were assessed by ANOVA using the
SPSS 13.0 (SPSS Inc., Chicago, IL, USA) statistical package pro-
gram. Signiﬁcant differences were accepted when P < 0.05 or
P < 0.01.
3. Results
3.1. Effects on neurological deﬁcit
After cerebral IR injury, neurological deﬁcit score of the model
group was signiﬁcantly higher than that of the sham group
(P < 0.01), whereas all the three treatment groups were lower than
the model group (P < 0.01) (Table 1).
3.2. Effects on brain glucose metabolism
The glucose metabolism in brain was  signiﬁcantly reduced in
the hippocampus region of the model group compared with that of
the sham operation group after cerebral IR injury (P < 0.01). Glu-
cose metabolism in injury brain while being treated with ASG
IV and ASG IV–TMPZ, was  increased signiﬁcantly (P < 0.05 and
P < 0.01, respectively), in the area compared with the model group.
Whereas, glucose metabolism of the ASG IV–TMPZ group was sig-
niﬁcantly recovered in the right area of compared with the ASG IV
group (P < 0.05), demonstrating a visible therapeutic effect of ASG
IV–TMPZ (Fig. 1). The 18F-FDG uptake of focal ischemic lesion in two
treatment groups was higher than in the model group (Table 2), of
which the ASG IV–TMPZ group showed best glucose metabolism
recovery.
3.3. Triphenyltetrazolium chloride evaluation
The infarct volume in the model group was  signiﬁcantly
increased than the sham group (P < 0.01). In contrast, the ASG
IV–TMPZ group showed the smallest infarct volume (0.182 ± 0.019,
P < 0.01), followed by the ASG IV group (0.213 ± 0.028, P < 0.01)
and the nimodipine group (0.195 ± 0.014, P < 0.01), compared
with the model group after treatment, as shown in Fig. 2 and
Table 3.
3.4. Drugs attenuated oxidative stress and determination of iNOSThe SOD activity was  signiﬁcantly decreased in the model group
(P < 0.01) compared with the sham group; whereas MDA  level and
iNOS content was  increased (P < 0.01). Although MDA  and iNOS
content in treatment group was decreased signiﬁcantly compared
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Fig. 1. 18FDG-PET images of activity of hibateral hippocampus regions glucose metabolism. Sham group (A), model group (B), astragaloside IV group (C), astragaloside
I
w
n
t
n
T
T
E
VV–tetramethylpyrazine group (D), nimodipine group (E).
ith the model group (P < 0.01). In the ASG IV–TMPZ (P < 0.01) and
imodipine groups (P < 0.01), SOD activity was signiﬁcantly higher
han in the ASG IV group, and the MDA  and iNOS content was sig-
iﬁcantly decreased compared with the ASG IV group as shown in
able 4.
able 2
ffects of different groups on brain glucose metabolism (nCi/cc) in hibateral hippocampu
Group n 
Sham operation 8 
Model  8 
Astragaloside IV 8 
Astragaloside IV–tetramethylpyrazine 8 
Nimodipine 8 
alues are mean ± SD.
* P < 0.01; signiﬁcantly lower compared with values of sham operation group.
** P < 0.01; signiﬁcantly higher compared with values of model group.
w P < 0.01; signiﬁcantly higher compared with values of astragaloside IV group.3.5. Expression of Caspase-3The expression of Caspase-3-mRNA in the model group was
signiﬁcantly increased compared with the sham group (P < 0.01).
Caspase-3 expression in the ASG IV (P < 0.05), ASG IV–TMPZ
s.
Left Right
7501.67 ± 24.906 7023.33 ± 50.123
7407.68 ± 51.160 4473.67* ± 86.002
7481.00 ± 93.258 5443.00** ± 52.000
7417.00 ± 68.462 6514.00**,w ± 22.338
7412.67 ± 18.502 6584.33** ± 85.471
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Fig. 2. 2,3,5-Triphenyltetrazolium chloride (TTC) staining to delineate rat brain infarcts of
model  group (B), astragaloside IV group (C), astragaloside IV–tetramethylpyrazine group 
Table  3
Infarct volume of different groups in brain cortex sections after cerebral IR with TTC
staining.
Group n Infarct volume
Sham operation group 8 0.000 ± 0.000
Model group 8 0.315* ± 0.031
Astragaloside IV group 8 0.245** ± 0.022
Astragaloside IV–tetramethylpyrazine 8 0.176**,w ± 0.014
Nimodipine group 8 0.206** ± 0.025
Values are mean ± SD.
* P < 0.01; signiﬁcantly higher compared with values of sham operation group.
** P < 0.01; signiﬁcantly lower compared with values of model group.
w P < 0.01; signiﬁcantly lower compared with values of astragaloside IV group. middle cerebral artery occlusion-induced focal cerebral ischemia. Sham group (A),
(D), nimodipine group (E).
(P < 0.01), however, nimodipine groups (P < 0.01) was decreased
signiﬁcantly compared with the model group. Although Caspase-
3-mRNA expression in both the ASG IV–TMPZ (P < 0.01) and the
nimodipine groups (P < 0.01) was lower than the ASG IV group
by real time quantitative PCR revealed the levels of expression of
Caspase-3-mRNA, as shown in Table 5.
3.6. Expression of Bcl-2Bcl-2 immunoreactivity of neural was quantiﬁed by light
microscopy and a computerized image analysis system. Expres-
sion of Bcl-2 immunoreactivity was  reduced in the model group
J. Yang et al. / Journal of Ethnopharmacology 140 (2012) 64– 72 69
Table 4
Determination of drugs on the activity of SOD, contents of MDA and iNOS.
Group n SOD (U/mg) MDA  (nmol/mg) iNOS (mol/L)
Sham operation group 8 51.89 ± 1.52 2.25 ± 0.08 6.73 ± 0.27
Model  group 8 32.54** ± 0.84 5.52* ± 0.28 26.20* ± 1.66
Astragaloside IV group 8 39.05www ± 1.36 3.45*** ± 0.10 16.76*** ± 0.90
Astragaloside IV–tetramethylpyrazine 8 45.33w ± 1.64 2.92ww ± 0.21 14.05ww ± 1.28
Nimodipine group 8 45.63www ± 2.63 2.67*** ± 0.12 11.80*** ± 1.25
Values are mean ± SD.
MDA, malondialdehyde; SOD, superoxide dismutase; iNOS, inducible nitric oxide synthase.
* P < 0.01; signiﬁcantly higher compared with values of sham operation group.
** P < 0.01; signiﬁcantly lower compared with values of sham operation group.
*** P < 0.01; signiﬁcantly lower compared with values of model group.
w P < 0.01; signiﬁcantly higher compared with values of model group and astragaloside IV group.
ww P < 0.01; signiﬁcantly lower compared with values of model group and astragaloside IV group.
wwwP < 0.01; signiﬁcantly higher compared with values of model group.
Fig. 3. B-cell lymphoma 2 (Bcl-2) immunostained tissue (magniﬁcation 200×) of middle cerebral artery occlusion-induced focal cerebral ischemia in rats. Sham group (A),
model  group (B), astragaloside IV group (C), astragaloside IV–tetramethylpyrazine group (D), nimodipine group (E).
70 J. Yang et al. / Journal of Ethnophar
Table 5
Real time-qPCR revealed the levels of Caspase-3 relative quantitative analysis after
reperfusion.
Group n 2−Ct of Caspase-3 mRNA
Sham operation group 6 0.53 ± 0.033
Model group 6 0.95* ± 0.070
Astragaloside IV group 6 0.88** ± 0.049
Astragaloside IV–tetramethylpyrazine 6 0.80*** ± 0.043
Nimodipine group 6 0.67*** ± 0.030
Values are mean ± SD.
Caspase-3; RT-qPCR, real time quantitative PCR.
* P < 0.01; signiﬁcantly higher compared with values of sham operation group.
** P < 0.05; signiﬁcantly lower compared with values of model group.
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l*** P < 0.01; signiﬁcantly lower compared with values of model group and astraga-
oside IV.
P < 0.01) compared with the sham group. Expression of Bcl-2
mmunoreactivity of the model group was signiﬁcantly lower
han that of the ASG IV group (P < 0.05), the ASG IV–TMPZ group
P < 0.01), and nimodipine group (P < 0.01). In the ASG IV- TMPZ
roup (P < 0.01) and nimodipine group (P < 0.01), the Bcl-2 level was
howed to be higher than ASG IV group (Table 6). As shown in Fig. 3,
cl-2 immunostained tissue (magniﬁcation, 200×) changes in pro-
ein expression of Bcl-2 in all groups after cerebral IR damage were
bserved by the immunohistochemical method.
. Discussion
Cerebral I/R injury, which results in cerebral infarction, is the
ain cause for the aggravation of brain dysfunction and cell death
Schaller and Graf, 2004). The early moments of reperfusion are
mportant in the pathogenesis at excessive formation of free radi-
als, cascade reactions, overload of calcium inside neurocytes, and
ytotoxic substance of excitatory amino acids are the main reasons
ontributing to cerebral IR injury. As the main cause for the aggrava-
ion of cerebral injury, acute inﬂammatory cascade reactions draw
peciﬁc attention (Danton and Dietrich, 2003; Huang et al., 2006).
CAO, a reliable, less invasive stroke model of temporary regional
schemia has been prompted by the extensive neurochemical data
lready available in rats, so as to reduce the rising cost of exper-
ments with larger animals, and the limitations of other rodent
odels of focal cerebral IR. Because cerebral cortex and hippocam-
us damage are the main event of brain ischemia in MCAO, the
eurons in hippocampus should be a target for this protection (Xing
t al., 2008). Neuroprotective effects of ASG IV–TMPZ were stud-
ed in the MCAO model in rats for the ﬁrst time. The neurological
core was used to evaluate the neuroprotective effects (Garcia et al.,
995). The neurological score was improved by treatment with ASG
V and ASG IV–TMPZ, which indicated the protective potential of
SG IV and ASG IV–TMPZ in focal cerebral ischemia. In the ASG IV
nd ASG IV–TMPZ groups, moderate focal deﬁcits were observed
able 6
he expression of Bcl-2 immunoreactive (numbers of positive cells/ﬁeld of vision).
Group n Bcl-2 protein
Sham operation group 50 34.92 ± 2.93
Model group 50 11.36* ± 2.44
Astragaloside IV group 50 12.94** ± 3.95
Astragaloside IV–tetramethylpyrazine 50 19.70*** ± 3.49
Nimodipine group 50 21.22w ± 3.94
alues are means ± SD.
* P < 0.01; signiﬁcantly lower compared with values of sham operation group.
** P < 0.05; signiﬁcantly higher compared with values of model group.
*** P < 0.01; signiﬁcantly higher compared with values of model group and astraga-
oside IV group.
w P < 0.01; signiﬁcantly higher compared with values of model group.macology 140 (2012) 64– 72
after full recovery from anesthesia. The neurologic deﬁcit scores
for rats in the ﬁve groups are presented in Table 1.
In our study, effects of both ASG IV and ASG IV–TMPZ produced
a signiﬁcant reduction in the infarct volume compared with MCAO-
induced focal cerebral ischemia model of stroke in rats. In addition
to study the effect of reduce the volume of cerebral infarction,
ASG IV–TMPZ signiﬁcantly inhibited the cerebral infarct induced by
MCAO compared with ASG IV, as demonstrated by the neurologic
deﬁcit score.
In previous study, we  have used 18F-FDG micro-PET to detect
many kinds of cerebrovascular diseases because of the consump-
tion of large amounts of glucose as an energy source. Micro-PET
has the large advantage to monitor the glucose metabolism non-
invasively and assess the early effects for cerebrovascular disease
therapy (Lubec et al., 2000; Cherry and Gambhir, 2001; Zhao et al.,
2009). In our study, we investigated glucose metabolic activity of
each region of hippocampus in all groups. The ratio of the ROIs
in model group compared with the sham group, and both ASG IV
group and ASG IV–TMPZ group were all increased. Furthermore
the effect of ASG IV–TMPZ was better than ASG IV in the recovery
of glucose metabolism. Obvious metabolic asymmetry in the right
and left hemisphere of rat after the operation was observed by 7 d
after cerebral IR, the hypometabolic region was  enlarged distinctly
in the three treatment groups, among which was  the smallest in
the ASG IV–TMPZ group, as shown in Fig. 1. The data of 18F-FDG
micro-PET images were consistent with the triphenyltetrazolium
chloride evaluation (Fig. 2). However, by 1 h and 6 h after MCAO,
the mild decrease of metabolic activity of glucose was observed in
the right brain (data not shown), whereas a signiﬁcant increase was
also evident on the border of the ischemic area (Read et al., 1998;
Sarrafzadeh et al., 2010).
Generation of excessive reactive oxygen species (ROS) dur-
ing reperfusion plays a major role in brain injury. Because of the
brain’s low activities of antioxidative enzymes, it is very vulnera-
ble to ROS induced by cerebral IR injury, which causes oxidative
damage to brain lipids, proteins, and DNA, leading to brain dys-
function and cell death. Experiment indicated that in cerebral
IR, SOD activity was  remarkably decreased and some antioxi-
dants up regulated SOD gene expression in rats after I/R injury
(Shahed et al., 2001). The content of MDA, one of the most sen-
sitive indicators of lipid peroxidation (Gutteridge, 1995), increased
remarkably. Besides superoxide, recent studies demonstrated that
iNOS increased in cerebral IR. It has demonstrated that inhibition of
apoptosis formation (active Caspase-3) and inﬂammatory response
(iNOS), resulting in a reduction in the infarct volume in ischemia-
reperfusion brain injury (Chang et al., 2007). The results of MDA,
iNOS level, and SOD activity were consistent with the reduction of
cerebral infarction as well as neurological recovery (Vaughan and
Delanty, 1999). In this experiment, we  also found that free radical
production may  be an important factor to represent an impor-
tant modulator after longer periods of cerebral IR. The effects of
ASG IV and ASG IV–TMPZ on brain MDA  content, SOD  activity, and
iNOS levels in MCAO–reperfusion rats are shown in Table 3. After
the experiment, we found that the levels of MDA  and iNOS in the
brain tissue in the model group were remarkably increased and
SOD activity was  remarkably decreased. In the ASG IV and ASG
IV–TMPZ groups, the levels of iNOS were reduced and the level
of SOD was  increased compared with the model group. These data
suggested that the antioxidant property of ASG IV–TMPZ could play
an important role in protecting the neurons, possibly by increasing
the endogenous defensive capacity of the brain to combat oxidative
stress induced by cerebral I/R.Caspase-3 is a major cell death effector protease in the adult and
neonatal nervous system (Le et al., 2002), and initiate the cleavage
of key cellular substrates (Namura et al., 1998; Zhou et al., 2003).
In our study, we  found that the level of Caspase-3 after ischemia
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as increased, connecting with the worsening of infarct severity,
hich means that the role of Caspase-3 was propagating tissue
amage. After cerebral I/R, the expression of Caspase-3 mRNA in
he model group compared with the sham operation group. The
aspase-3-mRNA expression of the ASG IV, ASG IV–TMPZ, and
imodipine groups was decreased signiﬁcantly compared with the
odel group. ASG IV–TMPZ played an important role in prevent-
ng expression of the Caspase 3 mRNA. The bcl-2 family members
re major regulators of the apoptotic process (Ivins et al., 1998;
ata et al., 1999; Solaroglu et al., 2006). In our experiment, we
nvestigated the immunoreactivity expression to study the protec-
ion by ASG IV–TMPZ of cortical neurons from cerebral IR injury.
cl-2 immunoreactivity of neural cells was quantiﬁed by using
ight microscopy and a computerized image analysis system. Our
esults showed that a signiﬁcant increase in the number of Bcl-2
mmunoreactivities in neural cells was found in the cortex in the
SG IV–TMPZ group among all three treatment groups, as shown in
able 5, which indicated that ASG IV–TMPZ has obvious protective
ffect on nerve cells.
Rats with large infarct volume showed a lower SOD and Bcl-2,
igher MDA, iNOS, Caspase-3, and lower glucose metabolism com-
ared with that of small infarcts (Zhang et al., 2003; Moro et al.,
005). Treatment drugs improving energy metabolism, scavenging
OS and inhibiting apoptosis of cerebral IR injury, among which
SG IV–TMPZ treatment showed the most signiﬁcant protective
ffect. However, it is believed that the technology of neural stem
ell transplantation and repetitive transcranial magnetic stimula-
ion combined with ASG IV may  have amazing protective effect to
erebral I/R injury in near future (Zhang et al., 2008; Gao et al.,
010).
. Conclusion
The synergistic protective effect of ASG IV–TMPZ is related to
mprove glucose metabolism and protect hippocampus neurons,
ollowed by increase the activity of SOD, the expression of Bcl-2 pro-
ein, mediate a portion of the inhibition of the reduction of oxidative
tress, and anti-apoptosis, followed by inhibition of apoptosis for-
ation and inﬂammatory response, resulting in a reduction in
he infarct volume in ischemia-reperfusion brain injury. 18F-FDG
icro-PET could be used to monitor the therapeutic response of
SG IV–TMPZ or ASG IV. Thus, ASG IV–TMPZ treatment may  repre-
ent an ideal approach to lowering the risk of or improving function
n cerebral IR injury.
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